← Leaderboards
David J Fulton
Augusta University
$11,867,025
Attributed
$19,626,659
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,626,659 · 11
By mechanism
R01$18,518,736 · 8
P01$1,024,919 · 2
F32$83,004 · 1
Top collaborators
- David W Stepp14 shared
- Scott A Barman12 shared
Most similar at Augusta University
Same institution · by research overlap
- Scott A Barman$6,157,524
- Tohru Fukai$10,473,455
- Rudolf Lucas$4,701,624
- Neal L Weintraub$17,807,491
- Laszlo Kovacs$760,760
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroBlood VesselsEndotheliumMediatingGenesMouse ModelFunctional DisorderMolecularCellsBlood FlowCardiovascular DiseasesAnimal ModelPhosphorylationUp-RegulationBlood PressureRegulationIndexingNitric OxidePathway InteractionsSignal TransductionKnockout MiceProductionGalectin 3
Grant awards (40)
Skeletal Muscle Health Protects Vascular Function in Obesity$766,920
R01 · FY2025 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$700,700
R01 · FY2025 · HL · contact PI
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$686,685
R01 · FY2024 · HL · contact PI
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$671,594
R01 · FY2024 · HL · contact PI
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$700,700
R01 · FY2023 · HL · contact PI
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$685,300
R01 · FY2023 · HL · contact PI
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$700,700
R01 · FY2022 · HL · contact PI
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$685,300
R01 · FY2022 · HL · contact PI
Circadian origins of vascular disease in obesity$685,300
R01 · FY2022 · HL
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$685,300
R01 · FY2021 · HL · contact PI
Circadian origins of vascular disease in obesity$685,300
R01 · FY2021 · HL
Circadian origins of vascular disease in obesity$683,631
R01 · FY2020 · HL
Circadian origins of vascular disease in obesity$678,625
R01 · FY2019 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2019 · HL · contact PI
Novel mechanistic pathways of cardiovascular disease in obesity$556,290
R01 · FY2018 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2018 · HL · contact PI
Novel mechanistic pathways of cardiovascular disease in obesity$556,290
R01 · FY2017 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2017 · HL · contact PI
Novel mechanistic pathways of cardiovascular disease in obesity$556,290
R01 · FY2016 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2016 · HL · contact PI
Novel mechanistic pathways of cardiovascular disease in obesity$555,374
R01 · FY2015 · HL
Metabolic Determinants of Cardiovascular Dysfunction in Obesity$398,066
R01 · FY2013 · HL
Metabolic Determinants of Cardiovascular Dysfunction in Obesity$427,860
R01 · FY2012 · HL
Modulation eNOS Coupling In Gram Positive Infection-Associated Acute Lung Injury$352,500
P01 · FY2012 · HL · contact PI
Metabolic Determinants of Cardiovascular Dysfunction in Obesity$427,860
R01 · FY2011 · HL
Tyrosine phosphorylation of endothelial nitric oxide synthase$367,500
R01 · FY2011 · HL · contact PI
Modulation eNOS Coupling In Gram Positive Infection-Associated Acute Lung Injury$350,150
P01 · FY2011 · HL · contact PI
Analytical Core Unit$322,269
P01 · FY2011 · HL · contact PI
Metabolic Determinants of Cardiovascular Dysfunction in Obesity$432,180
R01 · FY2010 · HL
Tyrosine phosphorylation of endothelial nitric oxide synthase$367,500
R01 · FY2010 · HL · contact PI
Metabolic Determinants of Cardiovascular Dysfunction in Obesity$441,000
R01 · FY2009 · HL
Tyrosine phosphorylation of endothelial nitric oxide synthase$367,500
R01 · FY2009 · HL · contact PI
Tyrosine phosphorylation of endothelial nitric oxide synthase$367,500
R01 · FY2008 · HL · contact PI
Tyrosine phosphorylation of endothelial nitric oxide synthase$367,188
R01 · FY2007 · HL · contact PI
Regulation of eNOS by Subcellular Targeting$279,279
R01 · FY2006 · HL · contact PI
Regulation of eNOS by Subcellular Targeting$286,000
R01 · FY2005 · HL
Regulation of eNOS by Subcellular Targeting$286,000
R01 · FY2004 · HL
Regulation of eNOS by Subcellular Targeting$311,000
R01 · FY2003 · HL
PI-3 KINASE AND AKT TO ENDOTHELIAL NITRIC OXIDE$43,772
F32 · FY2001 · HL
PI-3 KINASE AND AKT TO ENDOTHELIAL NITRIC OXIDE$39,232
F32 · FY2000 · HL